Related Experiment Video
Updated: Jul 19, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice
J A Fernández-Caballero1, M Alvarez1, N Chueca1
1Servicio de Microbiología, Complejo Hospitalario Universitario Granada-Hospital PTS, Instituto de Investigación Biosanitaria IBS, Granada, Spain.
Objective:
We aimed to evaluate the correct assignment of HCV genotype/subtypes 1a and 1b by cobas® HCV genotyping (GT) assay (Roche Molecular Diagnostics) compared with nonstructural protein 5B (NS5B) sequencing.
Patients And Methods:
Clinical samples from 153 patients submitted for HCV genotyping were studied. After genotyping with the cobas® HCV GT, sequencing of a 387 bp fragment in the NS5B gene and phylogenetic analysis was employed to compare genotyping results. Major discrepancies were defined as differences in the assigned genotype by cobas® HCV GT and NS5B sequencing (including genotype 1 subtypes 1a and 1b misclassification).
Results:
Overall agreement between the cobas® HCV GT and NS5B sequencing was 98%; all the 1a, 1b, 2, 3 and 4 genotypes identified by cobas® HCV GT were concordant with NS5B sequencing. Three samples tested "indetermined" by cobas® HCV GT assay and were genotyped as 1a, 3a, and 4d by NS5B sequencing.
Conclussion:
These results indicate that the cobas® HCV GT assay correctly identifies HCV genotypes, and points out the importance of additional methods based on DNA sequencing for resolving indeterminate results.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Rapid Identification of Pathogens
Automated Microbial Diagnostics
Hepatitis
Viral Hepatitis I: Introduction

